NTHI
NTHI clinical trials: NEONC TECHNOLOGIES HOLDINGS, INC.
Every trial on ClinicalTrials.gov where NEONC TECHNOLOGIES HOLDINGS, INC. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 4
- Trials linked
- 4
- As lead sponsor
- 0
- As collaborator
- 2
- Primary completions as lead sponsor, next 90 days
NTHI on the catalyst calendar · NTHI registry changes
- Primary completion Feb 28, 2027Sponsor estimatePhase 1/Phase 2NCT06047379Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain MetastasisNeonc Technologies, Inc. · Diffuse Astrocytoma, IDH-MutantRecruitingNTHILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2027Sponsor estimatePhase 1NCT06357377A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain TumorsNeonc Technologies, Inc. · Pediatric Tumor of CNSRecruitingNTHILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2026Sponsor estimatePhase 2NCT05023018NEO100 and High-Grade MeningiomaNeonc Technologies, Inc. · Residual, Progressive or Recurrent Grade II or III MeningiomaRecruitingNTHILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimatePhase 1/Phase 2NCT02704858Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated GliomaNeonc Technologies, Inc. · Glioblastoma MultiformeActive, not recruitingNTHILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 4 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner